Pridopidine Phase 3 Study in Huntington's Disease
This study is investigating a new drug, pridopidine, to see if it can slow down the progression of Huntington's disease (HD) in adults and if it's safe to use. Researchers want to know if pridopidine can improve overall symptoms of HD, including daily activities, thinking skills, movement, and quality of life over one year. Some participants will receive pridopidine, while others will get a placebo (a dummy pill with no active drug). Neither the participant nor the doctors will know who is getting which. All participants will take a pill twice a day for a year and have six clinic visits. After this first year, everyone will then receive pridopidine for two more years. This will help scientists understand how well the drug works.
Auf einen Blick
Worum geht es in dieser Studie?
Huntington's disease (HD) is a serious condition that affects the brain, causing problems with movement, thinking, and mental health. There isn't a cure yet, so researchers are constantly looking for new treatments that can slow down its effects or improve symptoms. This study focuses on a drug called pridopidine, aiming to see if it can help people with HD.
Specifically, the researchers want to find out two main things: firstly, whether pridopidine can slow down how much HD symptoms get worse over one year. Secondly, they want to understand if it helps with specific aspects of the disease, such as a person's ability to do daily tasks, their memory and thinking skills, their control over their body movements, and their overall quality of life. By comparing pridopidine to a placebo (a pill that looks the same but contains no active drug), they can get a clear picture of its potential benefits.
This type of study is really important because it helps doctors and patients understand if a new treatment is effective and safe. The information gathered from this research could lead to new ways to manage HD and potentially improve the lives of those living with the condition. It's a key step in bringing new medicines closer to people who need them.
Wichtige Erkenntnisse
- This study explores pridopidine as a potential new treatment for Huntington's disease.
- It aims to see if the drug can slow down symptoms and is safe.
- Participants take a pill twice daily for three years.
- The first year involves either the drug or a dummy pill; everyone gets the drug for the next two years.
- Regular clinic visits and check-ups are part of participating.
- Your medical care will not be affected if you choose not to join or decide to leave the study.
Wer könnte berechtigt sein?
To join this study, you would generally need to be an adult between 23 and 65 years old who has been diagnosed with Huntington's disease after the age of 21. Your diagnosis must be based on clear symptoms and a specific genetic test result.
There are also some medical conditions or medications that would prevent you from taking part. For example, if you have certain heart problems, a recent history of seizures, severe kidney or liver issues, or certain types of cancer, you might not be eligible. If you are pregnant, planning to become pregnant, or breastfeeding, you cannot join the study. Also, if you've recently used certain types of Huntington's disease medication or other specific drugs, you might not be able to participate.
The research team will carefully check all these details to make sure the study is safe for you and that the results will be clear and accurate. It’s important to remember that you shouldn't stop any current medication just to join this study.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Are you between 23 and 65 years old?
- Were you diagnosed with Huntington's disease (HD) after age 21?
- Have you not used certain specific HD medications (called ADMs) in the last six months?
- Are you not pregnant, planning to become pregnant, or breastfeeding?
- Do you not have severe heart, kidney, or liver problems, or certain other serious health issues?
Was beinhaltet die Teilnahme?
If you decide to join this study, here's what it would involve:
For the first year, you would take one study capsule (either pridopidine or a dummy pill) twice a day – once in the morning and once in the afternoon. During this year, you would visit the clinic six times for check-ups and tests. There will also be five phone calls with the study team to check on your safety.
After this initial year, all participants will then receive pridopidine for an additional two years. During these two years, you would continue to take pridopidine twice a day and would have six more clinic visits. The total duration of your participation in the study would be three years. Throughout the study, the medical team will be checking your health and how you're responding to the treatment.
Potenzielle Risiken und Vorteile
Locations (66)
- The University of Alabama at BirminghamVerifizierte PostleitzahlBirmingham, Vereinigte Staaten· Rekrutierung
- University of California, San DiegoVerifizierte PostleitzahlLa Jolla, Vereinigte Staaten· Rekrutierung
- UCLA Medizinisches ZentrumVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten· Noch nicht rekrutiert
- UC Davis Medical CenterVerifizierte PostleitzahlSacramento, Vereinigte Staaten· Noch nicht rekrutiert
- Georgetown UniversityVerifizierte PostleitzahlWashington D.C., Vereinigte Staaten· Noch nicht rekrutiert
- University of Miami-U Health Boca RatonVerifizierte PostleitzahlBoca Raton, Vereinigte Staaten· Noch nicht rekrutiert
- University of Florida (Norman Fixel Institute for Neurological Diseases)Verifizierte PostleitzahlGainesville, Vereinigte Staaten· Noch nicht rekrutiert
- Northwestern UniversitätVerifizierte PostleitzahlChicago, Vereinigte Staaten· Noch nicht rekrutiert
- Rush UniversitätsklinikumVerifizierte PostleitzahlChicago, Vereinigte Staaten· Noch nicht rekrutiert
- University of Kansas Medical CenterVerifizierte PostleitzahlKansas City, Vereinigte Staaten· Noch nicht rekrutiert
- Hereditary Neurological Disease CentreVerifizierte PostleitzahlWichita, Vereinigte Staaten· Rekrutierung
- Johns Hopkins UniversityVerifizierte PostleitzahlBaltimore, Vereinigte Staaten· Noch nicht rekrutiert
Häufige Fragen
Was ist das Hauptziel dieser Studie?
The main goal is to see if the drug pridopidine can slow down how Huntington's disease gets worse and if it is safe for people to use.
Was ist ein 'Placebo'?
A placebo is a pill that looks exactly like the study drug but doesn't contain any active medicine. It helps researchers compare the real drug's effects.
Wie lange werde ich an der Studie teilnehmen?
You would be in the study for a total of three years. The first year involves either pridopidine or a placebo, followed by two more years where everyone receives pridopidine.
Will I know if I'm getting the real drug or the placebo?
For the first year, neither you nor your doctors will know if you're receiving pridopidine or the placebo. This is to ensure fair and unbiased results.
What kind of visits will I have?
You will have regular clinic visits for check-ups and tests, as well as some safety phone calls, throughout the three years of the study.
Wie Sie mehr erfahren können
Prilenia Medical Information
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.